Quarterly report [Sections 13 or 15(d)]

Consolidated Financial Statements Details - Intangible Assets, Net (Details)

v3.25.1
Consolidated Financial Statements Details - Intangible Assets, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Intangible assets, net    
Cost $ 26,115 $ 26,115
Accumulated Amortization 750 206
Net Carrying Value $ 25,365 25,909
Estimated remaining life of intangible assets 11 years 8 months 12 days  
Projected amortization expense for the next five years    
2025 (excluding the three months ended March 31, 2025) $ 1,632  
2026 2,176  
2027 2,176  
2028 2,176  
2029 2,176  
Total 10,336  
Pulmokine - Seralutinib IP    
Intangible assets, net    
Cost 26,115 26,115
Accumulated Amortization 750 206
Net Carrying Value $ 25,365 $ 25,909